Jim Caggiano | Chief Executive Officer
Dendreon

Jim Caggiano, Chief Executive Officer, Dendreon

With nearly 30 years of experience in the biotech/pharmaceutical and medical device industries, Jim Caggiano is committed to advancing therapeutic options that improve the lives of patients. Having spent his career focused on areas of medicine where few or no effective options exist, including urology, gynecology and cardiology, he currently serves as chief executive officer of Dendreon Pharmaceuticals LLC. A seasoned and dynamic leader, Caggiano has a proven track record of creating value in turnaround situations and managing business transitions. He is credited with Dendreon’s resurgence as an exciting and growing enterprise aimed at bringing PROVENGE® (sipuleucel-T) – the company’s flagship product and the only immunotherapy treatment option for men with advanced prostate cancer – to the nearly 50,000 men who could benefit from this life-saving treatment. He successfully directed the divestiture of Allergan’s LAP-BAND to Apollo Endosurgery in 2013, and later developed and implemented the strategy for Dendreon’s sale to Sanpower Group in 2016. Earlier in his career, Caggiano held senior roles at Allergan, Inc., Abbott Laboratories and TAP Pharmaceuticals, where he led sales and marketing functions for Lupron®, a prostate cancer treatment. Caggiano received a B.S. in agricultural economics (business) from Cornell University and an M.B.A. from the Kellogg School of Management at Northwestern University.

Appearances:



Immunotherapy Conference Day 2 @ 09:40

PROVENGE®: Hits and misses, now success

  • Navigating the transition from clinical promise to commercial success
  • Marketplace challenges facing PROVENGE
  • Orchestrating a successful turnaround
  • What PROVENGE has taught us about the promise of immunotherapy

Immunotherapy Conference Day 2 @ 10:00

Panel discussion: Commercial strategies in immunotherapy

  • High level pharma companies come together to discuss their strategies for tackling cancer
last published: 12/Nov/18 11:05 GMT

back to speakers